| Identification | Back Directory | [Name]
1H-Benzimidazol-2-amine, N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- | [CAS]
875755-39-8 | [Synonyms]
1H-Benzimidazol-2-amine, N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- | [Molecular Formula]
C17H17N3 | [MOL File]
875755-39-8.mol | [Molecular Weight]
263.34 |
| Chemical Properties | Back Directory | [Boiling point ]
482.9±48.0 °C(Predicted) | [density ]
1.273±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 100mg/mL | [form ]
powder | [pka]
11.37±0.10(Predicted) | [color ]
white | [InChIKey]
XZIZUQSOFMLIIR-CQSZACIVSA-N | [SMILES]
C1(NC(N[C@@H]2CCCC3=C2C=CC=C3)=N4)=C4C=CC=C1 |
| Hazard Information | Back Directory | [Uses]
An aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels (SK1-3; Kd = 420 nM, 600 nM, and 730 nM for SK1, SK2, SK3, respectively) in a Ca2+-dependent manner. It mediates channel gating by interacting with gating structures deep within the inner pore vestibule where Ser507 and Ala532 are deemed to be important for inhibition. Interacts at a site that is distinct from the apamin binding site in SK channels. Can access high-affinity binding sites from both the inside and outside of the cell membrane. Does not affect QT intervals, but prolongs the atrial effective refractive period and prevents acetylcholine-induced atrial fibrillations in ex vivo and in vivo models. Also shown to reversibly block TRPM7 channel (IC50 = 1.6 mM) in smooth muscle cells, primary podocytes, HEK293 cells expressing TRPM7, and ventricular myocytes in a Mg2+-dependent manner and blocks the motility of cells in culture. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|